The Supreme Court’s May 2019 "Merck v. Albrecht" decision clarified that judges, not juries, should analyze a prescription drug maker’s federal preemption defense in failure-to-warn suits. Under "Albrecht," courts must decide whether companies could unilaterally add a warning under federal labeling rules. Our speakers will examine recent court decisions implicating warnings and preemption. Among the cases they will discuss is "Janssen Pharm. v. A.Y.," a state court decision that the company has appealed to the Supreme Court. The justices could rule on the certiorari petition as early as May 13.